Effect of intravitreal anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration on renal function

Nephrol Dial Transplant. 2023 Jun 30;38(7):1770-1772. doi: 10.1093/ndt/gfad035.

Authors

James E Neffendorf¹, Tracey Mare², Andrew R H Simpson¹, Cristina Soare¹, Varo Kirthi¹, Claire C Sharpe³, Timothy L Jackson^{1

3}

Affiliations

¹ King's Ophthalmology Research Unit, King's College Hospital, London, UK.
² Synnovis, King's College Hospital, London, UK.
³ Faculty of Life Sciences and Medicine, King's College London, London, UK.

PMID: 36764668
DOI: 10.1093/ndt/gfad035

No abstract available

MeSH terms

Angiogenesis Inhibitors / therapeutic use
Endothelial Growth Factors* / therapeutic use
Humans
Intravitreal Injections
Kidney / physiology
Macular Degeneration* / drug therapy
Receptors, Vascular Endothelial Growth Factor / therapeutic use
Recombinant Fusion Proteins / therapeutic use
Retrospective Studies
Treatment Outcome
Vascular Endothelial Growth Factor A

Substances

Endothelial Growth Factors
Angiogenesis Inhibitors
Vascular Endothelial Growth Factor A
Receptors, Vascular Endothelial Growth Factor
Recombinant Fusion Proteins